nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

01.03.2016 | Original Research

Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis

verfasst von: Fabian Finkelmeier, Se-Jong You, Oliver Waidmann, Robert Wolff, Stefan Zeuzem, Oliver Bähr, Jörg Trojan

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Brain metastases are rare in patients with colorectal cancer, but the incidence is expected to rise due to prolonged survival resulting from more effective regimens including anti-EGF-receptor and anti-angiogenic antibodies. Because of the potential fear of intracranial hemorrhage, patients with colorectal brain metastases have been excluded from clinical trials involving bevacizumab or aflibercept.

Patients

Five patients with colorectal brain metastases treated with bevacizumab-containing chemotherapy regimen following either neurosurgery, radiosurgery, or whole-brain radiotherapy were identified between 2009 and 2014. The clinicopathological data and outcomes for these patients were reviewed.

Results

Mean time to disease progression concerning brain metastases was 14.8 months (range 5–25). Overall survival was 26.2 months (range 7–42 months) and overall survival since diagnosis of brain metastases was 20.6 month (7–42). Best response was a partial response in two and a stable disease in three patients. Treatment-related adverse events were mild hypertension (grade 1), diarrhea (grade 1), and fatigue (grade 1). No intracranial hemorrhage was observed.

Conclusion

Bevacizumab in combination with chemotherapy is a feasible option for palliative treatment of patients with colorectal brain metastasis with a good safety profile.

Nur mit Berechtigung zugänglich

Ferlay J, Shin HR, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127(12):2893–917.CrossRef

Van der Pool AE, Damhuis RA, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population based series. Color Dis. 2012;14(1):56–61.CrossRef

Kopetz S, Chang GJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.PubMedCentralCrossRefPubMed

Heinemann V, Fischer von Weikersthal L, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol. 2013;31:2013 (suppl; abstr LBA3506).

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. Open label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64.CrossRefPubMed

Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.CrossRefPubMed

Cunningham D, Atkin W, Lenz HJ, Lynch HT, et al. Colorectal cancer. Lancet. 2010;375:1030–47.CrossRefPubMed

Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.CrossRefPubMed

Jung M, Ahn JB, Chang JH, Suh CO, Hong S, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neuro-Oncol. 2011;101(1):49–55.CrossRef

10.

Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.CrossRefPubMed

11.

Gerber HP, Dixit V, Ferrara N, et al. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998;273:13313–6.CrossRefPubMed

12.

Dvorak HF, Brown LF, Detmar M, Dvorak AM, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMedCentralPubMed

13.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5.CrossRefPubMed

14.

Folkman J. Tumor angiogenesis: therapeutic implications. NEJM. 1971;285:1182–6.CrossRefPubMed

15.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM. 2004;350:2335–42.CrossRefPubMed

16.

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer A, Figer R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed

17.

Giantano BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer, results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.CrossRef

18.

Bennouna J, Sastre J, Arnold D, Österlund P, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.CrossRefPubMed

19.

Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–50.PubMed

20.

Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. NEJM. 2006;355:2542–50.CrossRefPubMed

21.

Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.CrossRefPubMed

22.

Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255–61.CrossRefPubMed

23.

Archer V, Reck M, Sandler AB, et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol. 2008;26:15. abstr 8114.

24.

Therasse P, Arbuck SG, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed

25.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed

26.

Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269–78.CrossRefPubMed

27.

Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet. 2010;11:733–40.CrossRefPubMed

28.

Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624–30.PubMedCentralCrossRefPubMed

29.

Besse B, Le Moulec S, Senellart H, et al. Final overall survival (OS) results of a non comparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC patients with asymptomatic untreated brain metastases (BM)(BRAIN). J Clin Oncol. 2013; 31, (suppl; abstr 8059); ASCO Anual Meeting 2013; Abstract Number: 8059.

30.

Go PH, Klaassen Z, Meadows MC, Chamberlain R, et al. Gastrointestinal cancer and brain metastasis—a rare and omnious sign. Cancer. 2011;117(16):3630–40.CrossRefPubMed

31.

Cascino TL, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. J Neuro-Oncol. 1983;1:203–9.CrossRef

32.

Wronski M, Arbit E. Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer. 1998;85:1677–85.CrossRef

33.

Bartelt S, Momm F, Weissenberger C, Lutterbach J, et al. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J Gastroenterol. 2004;10:3345–8.PubMedCentralCrossRefPubMed

34.

Farnell GF, Buckner JC, Cascino TL, O’Connell MJ, et al. Brain metastases from colorectal carcinoma. The long term survivors. Cancer. 1996;78:711–6.CrossRefPubMed

35.

Hammoud MA, McCutcheon IE, Elsouki R, Schoppa D, et al. Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Ann Surg Oncol. 1996;3:453–63.CrossRefPubMed

36.

Suzuki Y, Yamaguchi T, Matsumoto H, Nakano D, et al. Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer. Dis Colon Rectum. 2014;57(1):56–63.CrossRefPubMed

37.

Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012; 4:CD003869. doi:10.1002/14651858.CD003869.pub3.

38.

Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black Kl, et al. Whole brain radiation therapy (WBRt) alone versus WBRt and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev. 2012; 9.

39.

O’Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O’Fallon JR, et al. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys. 2003;55:1169–76.CrossRefPubMed

40.

Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–34.CrossRefPubMed

41.

Poulsen NHS, Grunnet K, Sorensen M, Olsen P, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48:52–8.CrossRefPubMed

42.

Vredenburg JJ, Desjardins A, Hernon JE, Dowell JM, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–9.CrossRef

43.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.CrossRefPubMed

44.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. NEJM. 2014;370(8):699–708.PubMedCentralCrossRefPubMed

45.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. NEJM. 2014;370(8):709–22.CrossRefPubMed

46.

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–31.PubMedCentralCrossRefPubMed

Titel: Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis
verfasst von: Fabian Finkelmeier
Se-Jong You
Oliver Waidmann
Robert Wolff
Stefan Zeuzem
Oliver Bähr
Jörg Trojan
Publikationsdatum: 01.03.2016
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2016
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-015-9795-z

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis